Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28247897 | 0.98 | CYP2D6 (0.49) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL28247895 | 0.98 | CYP2D6 (0.49) | CA12CA1CA2CA9CYP2D6 | |
| Iodide SCHEMBL28247499 | 0.98 | CYP2D6 (0.49) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL9613513 | 0.82 | — | — | |
| SCHEMBL1147606 | 0.79 | CYP2D6 (0.45) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL9233647 | 0.79 | CYP2D6 (0.45) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL2413232 | 0.79 | CYP2D6 (0.45) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL698258 | 0.78 | CA12 (0.52) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL698257 | 0.78 | CA12 (0.52) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL28524553 | 0.77 | SMN1; SMN2 (0.45) | CA12CA1CA2CA9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109575045-A | Thienopyrimidines, preparation method, Pharmaceutical composition and its application | 南京红云生物科技有限公司 | 2019-04-05 | — | — | CN | claimed |
| CN-108042546-A | Morpholinyl acetylamino benzo [d] azepine * bases quinazoline compounds are preparing the application in treating uterine neck cancer drug | 浙江工业大学 | 2018-05-18 | — | — | CN | claimed |
| CN-108017621-A | Morpholinyl acetylamino dimethoxy benzo [d] azepine * bases quinazoline compounds and preparation and application | 浙江工业大学 | 2018-05-11 | — | — | CN | claimed |
| CN-107698603-A | Thienopyrimidines, its preparation method, Pharmaceutical composition and its application | 厦门大学 | 2018-02-16 | — | — | CN | claimed |
| US-20110306572-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2] | TRAGARA PHARMACEUTICALS, INC (US) | 2011-12-15 | — | — | US | claimed |
| EP-0912570-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2003-09-10 | — | — | EP | claimed |
| EP-0912572-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2003-01-15 | — | — | EP | claimed |
| US-6391874-B1 | ANTICARCINOGENIC AGENTS; SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | claimed |
| US-6207669-B1 | IN TREATMENT OF CANCER AND PSORIASIS | GLAXO WELLCOME INC. | 2001-03-27 | — | — | US | claimed |
| US-6174889-B1 | PROTEIN TYROSINE KINASE INHIBITORS RELATED TO BIOISOSTERES OF QUINOLINE AND QUINAZOLINE DERIVATIVES; ANTICARCINOGENIC AND -TUMOR AGENTS; PSORIASIS; RESTENOSIS; RHEUMATOID ARTHRITIS, AUTOIMMUNE DISEASE, ALLERGY, ASTHMA AND GRAFT REJECTION | GLAXO WELLCOME INC. | 2001-01-16 | — | — | US | claimed |
| EP-0912559-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | claimed |
| WO-1998002434-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | claimed |
| US-5688913-A | OLIGOPEPTIDES AS ANTIINFLAMMATORY AGENTS | CYTEL CORPORATION (US) | 1997-11-18 | — | — | US | claimed |
| EP-4417607-A1 | HETEROCYCLIC COMPOUND AS SOS1 INHIBITOR AND USES THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2024-08-21 | — | — | EP | disclosed |
| CN-117957226-A | Heterocyclic compounds as SOS1 inhibitors and uses thereof | 南京再明医药有限公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2023041049-A1 | HETEROCYCLIC COMPOUND AS SOS1 INHIBITOR AND USES THEREOF | 江苏先声药业有限公司 | 2023-03-23 | — | — | WO | disclosed |
| EP-0061623-A1 | Process for dyeing or printing paper, and cationic phthalocyanine dyes | BASF Aktiengesellschaft (DE) | 1982-10-06 | — | — | EP | disclosed |
| US-4266003-A | Silver halide photographic emulsions | FUJI PHOTO FILM CO., LTD. (JP) | 1981-05-05 | — | — | US | disclosed |
| US-4252801-A | ANTIARRHYTHMIA AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1981-02-24 | — | — | US | disclosed |
| US-4252801-A | ANTIARRHYTHMIA AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1981-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306572-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2] | ERBB2, EGFR, ERBB3 | CA12 505/4885CA1 1238/4885CA2 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.